1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
    Review

    Motzer, R. J.; Taylor, M. H.; Evans, T. R. J.; Okusaka, T.; Glen, H.; Lubiniecki, G. M.; Dutcus, C.; Smith, A. D.; Okpara, C. E.; Hussein, Z.; more...
    Expert Review of Anticancer Therapy (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial
    Journal Article

    El-Khoueiry, A. B.; Meyer, T.; Cheng, A. L.; Rimassa, L.; Sen, S.; Milwee, S.; Kelley, R. K.; Abou-Alfa, G. K.
    BMC Cancer (2022)

    Fulltext@MSK | Save
  • Dose-response modeling in high-throughput cancer drug screenings: An end-to-end approach
    Journal Article

    Tansey, W.; Li, K.; Zhang, H.; Linderman, S. W.; Rabadan, R.; Blei, D. M.; Wiggins, C. H.
    Biostatistics (2022)

    Fulltext@MSK | Save
  • Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
    Journal Article

    Mazza, G. L.; Petersen, M. M.; Ginos, B.; Langlais, B. T.; Heon, N.; Gounder, M. M.; Mahoney, M. R.; Zoroufy, A. J.; Schwartz, G. K.; Rogak, L. J.; more...
    Quality of Life Research (2022)

    Fulltext@MSK | Save
  • Cisplatin, neoadjuvant chemotherapy and bladder cancer
    Editorial

    Herr, H.; Soloway, M.
    Urology (2022)

    Fulltext@MSK | Save
  • GCN2 kinase activation by ATP-competitive kinase inhibitors
    Journal Article

    Tang, C. P.; Clark, O.; Ferrarone, J. R.; Campos, C.; Lalani, A. S.; Chodera, J. D.; Intlekofer, A. M.; Elemento, O.; Mellinghoff, I. K.
    Nature Chemical Biology (2022)

    Fulltext@MSK | Save
  • Engineering CAR-T cells to activate small-molecule drugs in situ
    Journal Article

    Gardner, T. J.; Lee, J. P.; Bourne, C. M.; Wijewarnasuriya, D.; Kinarivala, N.; Kurtz, K. G.; Corless, B. C.; Dacek, M. M.; Chang, A. Y.; Mo, G.; more...
    Nature Chemical Biology (2022)

    Fulltext@MSK | Save
  • Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma
    Journal Article

    McIntyre, C. A.; Cohen, N. A.; Goldman, D. A.; Gonen, M.; Sadot, E.; O'Reilly, E. M.; Varghese, A. M.; Yu, K. H.; Balachandran, V. P.; Soares, K. C.; more...
    Journal of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Inhibition of microtubule dynamics in cancer cells by indole-modified latonduine derivatives and their metal complexes
    Journal Article

    Wittmann, C.; Sivchenko, A. S.; Bacher, F.; Tong, K. K. H.; Guru, N.; Wilson, T.; Gonzales, J.; Rauch, H.; Kossatz, S.; Reiner, T.; more...
    Inorganic Chemistry (2022)

    Fulltext@MSK | Save
  • Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
    Journal Article

    Yu, K. H.; Ozer, M.; Cockrum, P.; Surinach, A.; Wang, S.; Chu, B. C.
    Cancer Medicine (2021)

    Fulltext@MSK | Save